Product/Composition:- | Dicloxacillin Capsules |
---|---|
Strength:- | 250 mg, 500 mg |
Form:- | Oral Capsules |
Reference Brands:- | Dynapen(US) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Dicloxacillin inhibits bacterial cell wall synthesis by targeting penicillin-binding proteins, leading to bacterial lysis. It is effective against penicillinase-producing staphylococci. Benefits include targeted treatment of skin, soft tissue, and bone infections, rapid action, high efficacy, and safety when used as prescribed, especially in resistant staphylococcal infections.
Dicloxacillin capsules are approved in the EU and US for treating penicillinase-producing staphylococcal infections. In the EU, brands like Dynapen are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing standards. In the US, FDA approval relies on extensive clinical data and biosimilarity assessments, with generic options available. Both regions require detailed dossiers and pharmacovigilance plans for approval and ongoing safety monitoring. For expert support with regulatory dossiers, compliance, and registration, visit PharmaTradz. We facilitate efficient market access for dicloxacillin capsules, ensuring adherence to European and US standards for safe, effective antibiotic therapy in resistant bacterial infections.